September 10, 2019
Daiichi Sankyo said on September 9 that it has submitted a new drug application in Japan for its hoped-to-be-blockbuster DS-8201 (trastuzumab deruxtecan), a HER2-targeting antibody drug conjugate (ADC), for the treatment of HER2-positive metastatic breast cancer. The filing is based...read more